Los Angeles Capital Management LLC Sells 35,733 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Los Angeles Capital Management LLC decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 15.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 194,737 shares of the company’s stock after selling 35,733 shares during the period. Los Angeles Capital Management LLC owned 0.06% of Amneal Pharmaceuticals worth $2,454,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Amneal Pharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock valued at $179,729,000 after purchasing an additional 403,582 shares during the last quarter. Rubric Capital Management LP raised its position in Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amneal Pharmaceuticals by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock valued at $54,361,000 after purchasing an additional 133,764 shares during the last quarter. Nantahala Capital Management LLC raised its position in Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Amneal Pharmaceuticals by 75.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after purchasing an additional 1,611,698 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.30% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Stock Performance

AMRX stock opened at $14.69 on Wednesday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $7.53 and a fifty-two week high of $15.42. The business’s 50 day moving average price is $12.82 and its two-hundred day moving average price is $13.02. The company has a market capitalization of $4.69 billion, a price-to-earnings ratio of 38.66 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million during the quarter. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. UBS Group assumed coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target for the company. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays upped their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Finally, Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.